College athletics are in the news these days. One of the reasons: the O’Bannon decision, in which the court rejected the NCAA’s amateurism defense and found an antitrust violation when students were not paid for for the use of their names, images, and likenesses. In this article, Prof. Carrier summarizes the case as well as … Continue reading NCAA v. O’Bannon decision: A bombshell for college athletics…
Author: Michael Carrier
WSJ’s Q&A with Michael Carrier
The Wall Street Journal published Why the FTC Lawsuit over Pay-To-Delay Deals Matters – Carrier Explains, a Q&A with Michael Carrier. Carrier discussed the Federal Trade Commission’s lawsuit, which alleged antitrust violations by Abbott for filing frivolous patent litigation and by Abbott and Teva for entering into a settlement to delay generic entry. Carrier explained … Continue reading WSJ’s Q&A with Michael Carrier…
Michael Carrier on Bloomberg Radio on Lawsuit Against Alzheimer’s Manufacturer
The New York Attorney General filed a lawsuit against Actavis and Forest for pulling the old version of its Alzheimer’s treatment Naminda. In this interview with Bloomberg Radio, Professor Carrier explores the consequences of this development.
What You Need To Know About Standard Essential Patents
In the past several years, standard essential patents, or “SEPs,” have exploded onto the scene. Courts and enforcement agencies around the world have grappled with the nuances they present. What exactly are SEPs? What do attorneys need to know about SEPs? In his recent article, Professor Carrier answers these questions. After presenting the setting in … Continue reading What You Need To Know About Standard Essential Patents…
Michael Carrier testifies to U.S. Senate committee
http://www.c-spanvideo.org/program/PatentS Michael Carrier testified before the U.S. Senate Judiciary Committee’s Subcommittee on Antitrust, Competition Policy and Consumer Rights at a hearing entitled “Pay-for-Delay Deals: Limiting Competition and Costing Consumers” that was televised on C-SPAN. He provided support for congressional legislation to address the problem of settlements by which brand-name drug companies pay generics to delay … Continue reading Michael Carrier testifies to U.S. Senate committee…